Lipocomb

Ezetimibe, the active ingredient in Lipocomb, is a Statin / Cholesterol absorption inhibitor combination presented as an oral dosage form for oral use. It lowers elevated low‑density lipoprotein cholesterol (LDL‑C) and is indicated for primary hypercholesterolemia, mixed dyslipidemia and familial hypercholesterolemia in adults.

GNH USA supplies Lipocomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipocomb is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways.

Primary hypercholesterolemia: reduces LDL‑C to recommended therapeutic targets. Mixed dyslipidemia: improves the overall lipid profile, lowering triglycerides and raising HDL‑C. Familial hypercholesterolemia: provides additional LDL‑C reduction when statin monotherapy is insufficient.

Lipocomb may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhoea. - Elevated liver enzymes: mild transaminase rise. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Hepatotoxicity: significant liver injury indicated by marked enzyme elevation. - Acute renal failure: sudden loss of kidney function. - Severe hypersensitivity: rash, angioedema or anaphylaxis. - Thrombocytopenia: low platelet count. - Myocardial infarction: rare but reported in high‑risk patients.

Before initiating Lipocomb, consider the following safety measures.

Liver function monitoring: obtain baseline transaminases and repeat periodically. Renal impairment: adjust therapy in patients with severe kidney disease. Drug‑induced myopathy: assess risk when combined with other statins or fibrates. Pregnancy and lactation: avoid use unless clearly indicated by a physician. Alcohol consumption: limit intake as it may increase liver toxicity. Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Lipocomb can interact with several medication classes; awareness of the interaction severity guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure. - Cyclosporine: markedly raises rosuvastatin plasma levels, raising myopathy risk. - Gemfibrozil: synergistic increase in statin‑related muscle toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption. - Warfarin: potential alteration of INR, requiring closer monitoring. - Niacin: may increase risk of hepatotoxicity. - Digoxin: slight increase in serum concentrations. - Antihypertensives: monitor blood pressure as lipid‑lowering therapy can affect vascular tone.